Baseline characteristics in patients with low concentrations of hs-cTnT in the emergency department
| Peak hs-cTnT<5 ng/L | Peak hs-cTnT 5–14 ng/L | |
| Number of patients (row, %) | 69 090 (62) | 42 826 (38) |
| Age (years), median (IQR) | 44 (33–54) | 62 (50–72) |
| Women, n (%) | 39 368 (57) | 17 360 (41) |
| Comorbidities | ||
| Prior MI, n (%) | 1224 (1.8) | 3176 (7.4) |
| Prior revascularisation, n (%) | 1442 (2.1) | 3849 (8.9) |
| Prior stroke, n (%) | 563 (0.8) | 1597 (3.7) |
| Heart failure, n (%) | 711 (1.0) | 2295 (5.4) |
| Diabetes, n (%) | 2091 (3.0) | 4244 (9.9) |
| Hypertension, n (%) | 5829 (8.4) | 12 691 (29) |
| Atrial fibrillation, n (%) | 1269 (1.8) | 3515 (8.2) |
| Dialysis, n (%) | 23 (0.03) | 62 (0.1) |
| COPD, n (%) | 594 (0.9) | 1608 (3.7) |
| Laboratory data | ||
| First hs-cTnT concentration (ng/l), median (IQR) | n/a | 7 (6–10) |
| Haemoglobin (g/l), median (IQR) | 140 (131–150) | 142 (133–152) |
| Number of patients with>1 hs-cTnT measured, n (%) | 17 067 (25) | 18 697 (44) |
| Peak hs-cTnT concentration (ng/l), median (IQR) | n/a | 8 (6-10) |
| Delta-hs-cTnT concentration (ng/l), median (IQR) | n/a | 0 (−1, 1) |
| eGFR (mL/min/1.73 m2) | ||
| >60 | 68 076 (99) | 38 533 (90) |
| 30–59 | 864 (1.3) | 4127 (10) |
| <30 | 150 (0.2) | 166 (1.1) |
| Medication | ||
| Aspirin, n (%) | 3523 (5.1) | 8553 (20) |
| Any platelet inhibitor*, n (%) | 3752 (5.4) | 9289 (22) |
| Beta-blockers, n (%) | 5464 (7.9) | 10 735 (25) |
| ACEi/ARB, n (%) | 6163 (8.9) | 12 491 (29) |
| Statins, n (%) | 4676 (6.8) | 9611 (22) |
| OAC†, n (%) | 811 (1.2) | 2337 (5.5) |
Categorical and continuous variable data were compared between groups using χ2 and the Wilcoxon rank-sum test, with p-values of<0.001 throughout.
*Includes treatment with aspirin or P2Y12 inhibitors clopidogrel, ticagrelor, dipyradimol and prasugrel.
†Includes treatment with DOAC or Warfarin.
ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; hs-cTnT, high-sensitivity cardiac troponin T; MI, myocardial infarction; Nt-pro-BNP, N-terminal pro b-type natriuretic peptide; OAC, oral anticoagulants.